|Podcasts|May 15, 2018

Episode 8: CFO Insights From the Field

Author(s)Michelle Maskaly, Christen Harm

Episode 8 highlights Tim Sullivan, CFO of Apellis Pharmaceuticals, who provides listeners an inside look at what it takes to be the CFO of a development-stage biotch company, and what business skills someone needs to succeed in that type of position.

Episode 8 highlights Tim Sullivan, CFO of Apellis Pharmaceuticals, who provides listeners an inside look at what it takes to be the CFO of a development-stage biotech company, and what business skills someone needs to succeed in that type of position.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 26th, 2026

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

October 26th, 2026

The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki

Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

October 23rd, 2026

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.

October 23rd, 2026

Building Biopharma Manufacturing for Speed, Scale, and Flexibility

Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

October 20th, 2026

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.

Trending on PharmExec

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

Episode 8: CFO Insights From the Field

Related to this article

Trending on PharmExec

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica

Evidence With Purpose: Making Real-World Research Better, Not Just Faster

Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin